-
公开(公告)号：AU2007320657B8
公开(公告)日：2012-09-20
申请号：AU2007320657
申请日：2007-11-13
Applicant: CELLMID LTD
Inventor： MATSUI TAKASHI , ITO TAKANORI , MURAMATSU TAKASHI , UNO TSUKASA , HAYASHIBARA MASATOSHI
IPC: C07K16/32 , A61K39/395 , A61P35/00 , A61P35/04 , A61P37/00 , C12N5/10 , C12N15/02 , C12N15/09 , C12P21/08
Abstract: It is intended to provide an antibody which inhibits the function of midkine. An antibody which recognizes an epitope consisting of amino acid residues 62 to 104 of midkine or a fragment thereof; DNA encoding the antibody or a fragment thereof; a recombinant vector which contains the DNA; a transformant which has the vector or a hybridoma which produces the antibody; a method for producing the antibody by allowing the transformant or hybridoma to produce the antibody or a fragment thereof and collecting the resulting antibody or fragment thereof; a pharmaceutical composition containing the antibody or a fragment thereof as an active ingredient; and a diagnostic agent containing the antibody or a fragment thereof as an active ingredient.
-
公开(公告)号：JP2011063612A
公开(公告)日：2011-03-31
申请号：JP2010259684
申请日：2010-11-22
Applicant: Cellmid Ltd , セルミド リミテッド
Inventor： MURAMATSU TAKASHI , INO KAZUHIKO , MURAMATSU TOSHIKO , TORII SHUHEI
IPC: A61K45/00 , A61K31/7088 , A61K39/395 , A61P41/00 , A61P43/00
CPC classification number: A61K31/7088 , C07K16/22
Abstract: PROBLEM TO BE SOLVED: To provide a pharmaceutical agent for preventing post-laparotomy adhesion.
SOLUTION: The invention provides an oligonucleotide that suppresses the expression of midkine or an antibody that suppresses the function of midkine, the midkine which is known as a growth factor that enhances cell growth, migration, and survival, and is known for participating in inflammatory responses by promoting the migration of neutrophils and macrophages to inflammatory sites. The oligonucleotide is an antisense oligonucleotide which strongly suppresses midkine expression, inhibits its mRNA translation by hybridizing to midkine mRNA, and inhibits midkine synthesis. An anti-midkine antibody which is an antibody biniding to the midkine may be obtained as a polyclonal or monoclonal antibody.
COPYRIGHT: (C)2011,JPO&INPITAbstract translation: 待解决的问题：提供用于防止剖腹后粘连的药剂。 解决方案：本发明提供了抑制中期因子或抑制中期因子功能的抗体的寡核苷酸，称为增强细胞生长，迁移和存活的生长因子的中期因子，并且参与已知 通过促进中性粒细胞和巨噬细胞迁移到炎症部位的炎症反应。 寡核苷酸是强烈抑制中期因子表达的反义寡核苷酸，通过与midkine mRNA杂交抑制其mRNA翻译，并抑制中期因子合成。 可以作为多克隆或单克隆抗体获得作为中期因子二联体抗体的抗中期因子抗体。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：AU2017225906A1
公开(公告)日：2018-10-11
申请号：AU2017225906
申请日：2017-03-01
Applicant: CELLMID LTD
Inventor： JONES DARREN , HALASZ MARIA , LIEDERT ASTRID , HAFFNER-LUNTZER MELANIE , IGNATIUS ANITA
IPC: A61K39/395 , A61P19/08
Abstract: The present disclosure relates to methods and reagents for treating bone disorders and/or increasing bone healing. In particular, present disclosure relates to the use of isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (hereinafter, referred to as "MK") in the treatment of bone disorders and/or to increase bone healing.
-
公开(公告)号：AU2015333590A1
公开(公告)日：2017-04-20
申请号：AU2015333590
申请日：2015-10-14
Applicant: CELLMID LTD
Inventor： HALASZ MARIA , JONES DARREN , MERTENS NICO , CUNNAH PHILLIP
IPC: C07K16/22 , A61K39/395 , A61P29/00 , A61P35/00
Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
-
公开(公告)号：AU2014361754A1
公开(公告)日：2016-06-23
申请号：AU2014361754
申请日：2014-12-12
Applicant: CELLMID LTD
Inventor： YAMAMOTO MASAKUNI , NAMEKATA MASAO , YAMAUCHI KOICHI , MATSUMOTO TAKEO , JONES DARREN ROSS , HALASZ MARIA
IPC: A61K31/122 , A61K8/34 , A61K8/35 , A61K8/37 , A61K31/045 , A61K31/22 , A61P17/00 , A61P17/14 , A61Q7/00
Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signalling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signalling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.
-
Patent Agency Ranking
公开(公告)号：AU2649400A
公开(公告)日：2000-08-29
申请号：AU2649400
申请日：2000-02-10
Applicant: CELLMID LTD
Inventor： CLANCY ROBERT LLEWELLYN , GLEESON MAREE
IPC: G01N33/53 , G01N20060101 , G01N33/50 , G01N33/68
Abstract: The present invention is concerned with methods for determining predisposition to infection in a subject exposed to stressors. In particular the present invention is concerned with methods of assessing the risk of susceptibility to infection in a subject by monitoring the levels of IgA and IgA1.
-
公开(公告)号：AU2015333590B2
公开(公告)日：2021-03-11
申请号：AU2015333590
申请日：2015-10-14
Applicant: CELLMID LTD
Inventor： HALASZ MARIA , JONES DARREN , MERTENS NICO , CUNNAH PHILLIP
IPC: C07K16/22 , A61K39/395 , A61P29/00 , A61P35/00
Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
-
公开(公告)号：ES2426368T3
公开(公告)日：2013-10-22
申请号：ES08711071
申请日：2008-02-08
Applicant: CELLMID LTD , UBE INDUSTRIES , UNIV NAGOYA NAT UNIV CORP
Inventor： ISHIHARA KAZUAKI , KUGIMOTO JUNICHI , KAWAI JOJI
IPC: C07D201/04 , C07B61/00 , C07D225/02
Abstract: Procedimiento para producir laurolactama, que comprende las etapas de: (a) hacer reaccionar ciclododecanona con hidroxilamina en una disolución acuosa en presencia de una cantidad enexceso de ciclododecanona o un disolvente para producir oxima de ciclododecanona (a continuación en el presentedocumento, denominada "etapa de formación de oxima"); (b) separar la mezcla de reacción obtenida tras dicha etapa de formación de oxima en una fase de aceite y unaacuosa y recoger una disolución de oxima de ciclododecanona de la fase de aceite (a continuación en el presentedocumento, denominada "etapa de separación de fases de aceite/acuosa"); (c) retirar agua disuelta de dicha disolución de oxima de ciclododecanona que se recoge como una fase de aceite endicha etapa de separación de fases de aceite/acuosa, mediante lo cual se reduce el contenido de agua residual en ladisolución de oxima de ciclododecanona hasta 1000 ppm o menos (a continuación en el presente documento,denominada "etapa de deshidratación"); (d) producir laurolactama a partir de oxima de ciclododecanona mediante una reacción de transposición usando uncompuesto que contiene anillo aromático como catalizador de transposición (a continuación en el presentedocumento, denominada "etapa de transposición"), en el que el anillo aromático en dicho compuesto que contieneanillo aromático tiene una estructura (1) que comprende al menos un átomo de carbono que tiene un grupo salientecomo miembro de anillo del anillo aromático y (2) que comprende al menos dos átomos de carbono que tienen ungrupo electroatractor como miembros de anillo del anillo aromático, y (3) en el que, tres de los átomos de nitrógenoy/o los átomos de carbono que tienen un grupo electroatractor, siendo cada uno de ellos un miembro de anillo delanillo aromático, están en las posiciones orto y para con respecto al átomo de carbono que tiene un grupo salientedescrito en el punto (1); en el queel anillo aromático se selecciona del grupo que consiste en anillos aromáticos monocíclicos o policíclicos, anillosaromáticos policíclicos condensados y heterociclos aromáticos; el grupo saliente se selecciona del grupo que consiste en halógeno, sulfoniloxilo, haluro de sulfonilo, diazonio yhaluro de carbonilo, y el grupo electroatractor se selecciona del grupo que consiste en ciano, trifluorometilo, triclorometilo, nitro, haluro,carbonilo y sulfonilo; y (e) separar la laurolactama producida de la mezcla de reacción tras dicha etapa de transposición y purificar lalaurolactama (a continuación en el presente documento, denominada "etapa de separación/purificación").
-
公开(公告)号：AU2014361754B2
公开(公告)日：2020-04-30
申请号：AU2014361754
申请日：2014-12-12
Applicant: CELLMID LTD
Inventor： YAMAMOTO MASAKUNI , NAMEKATA MASATO , YAMAUCHI KOICHI , MATSUMOTO TAKEO , JONES DARREN ROSS , HALASZ MARIA
IPC: A61K31/122 , A61K8/34 , A61K8/35 , A61K8/37 , A61K31/045 , A61K31/22 , A61P17/00 , A61P17/14 , A61Q7/00
Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signalling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signalling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.
-
公开(公告)号：ES2405357T3
公开(公告)日：2013-05-30
申请号：ES06746805
申请日：2006-05-24
Applicant: CELLMID LTD , CELL SIGNALS INC
Inventor： KADOMATSU KENJI , BANNO HIROSHI , TAKEI YOSHIFUMI , KOMORI KIMIHIRO , MURAMATSU T , SAKUMA SADATOSHI
Abstract: Una composición farmacéutica para su uso en el tratamiento o prevención de la vasculopatíaobstructiva resultado de la restenosis tras la cirugía vascular reparadora que comprende: una construcción de ácidonucleico que inhibe la expresión del gen midkina mediante interferencia de ARN en el que dicha construcción deácido nucleico comprende un ARNip que tiene como diana al menos una porción del ARNm que codifica la proteínamidkina, y una molécula de colágeno, en la que el sitio de administración es la capa externa del vaso sanguíneo delsitio de la vasculopatía obstructiva.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.017 seconds)
